Synthesis and biological evaluation of thiazolidine-2-thione derivatives as novel xanthine oxidase inhibitors

文献类型： 外文期刊

第一作者： Wang, Mu-Xuan

作者： Wang, Mu-Xuan;Lv, Shen-Ming;Wang, Chun-Gu;Wang, Jia-Wei;Liao, Zhi-Xin;Wang, Mu-Xuan;Lv, Shen-Ming;Wang, Chun-Gu;Wang, Jia-Wei;Liao, Zhi-Xin;Qin, Hong-Wei;Liu, Chao;Chen, Jia-Shu;Chen, Ying-Ying;Sun, Jin-Yue

作者机构：

期刊名称：PLOS ONE （ 影响因子：3.7； 五年影响因子：3.8 ）

ISSN： 1932-6203

年卷期： 2022 年 17 卷 5 期

页码：

收录情况： SCI

摘要： Xanthine oxidase (XO) is a key enzyme in the generation and development of hyperuricemia. Thiazolidine-2-thione, a typical heterocyclic compound, have been widely used in the field of drug synthesis. In this study, a series of novel thiazolidine-2-thione derivatives were synthesized as XO inhibitors, and the XO inhibitory potencies of obtained compounds were evaluated by in vitro enzyme catalysis. The result shown that compound 6k behaved the strongest XO inhibitory activity with an IC50 value of 3.56 mu mol/ L, which was approximately 2.5-fold more potent than allopurinol. The structure-activity relationship revealed that the phenyl-sulfonamide group was indispensable for thiazolidine-2-thione derivatives to produce XO inhibitory activity. The enzyme inhibition kinetics analyses confirmed that compound 6k exerted a mixed-type XO inhibition. Additionally, the molecular docking results suggested that the 4-fluorophenyl-sulfonyl moiety could interact with Gly260 and Ile264 in the innermost part of the active pocket through 2 hydrogen bonds, while the thiazolidi-nethione moiety could form two hydrogen bonds with Glu263 and Ser347 in hydrophobic pockets. In summary, the results described above suggested that compound 6k could be a valuable lead compound for the treatment of hyperuricemia as a novel XO inhibitor.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序